Where it comes from
- Made in
- Granulosa cells of the dominant follicle, the corpus luteum, and the placenta
- Sent out by
- Peaks at mid-cycle and in the luteal phase; high through pregnancy
- Acts on
- Pituitary gonadotrophs (FSH)
- Ovary (local)
What it does
- Shuts off FSH once a follicle has been chosen, so only one ovulates
- Its fall is one of the earliest signs of reproductive ageing, before FSH rises 1
- A readout of corpus luteum and placenta rather than a target for treatment
In medicine
- The fourth marker of the second-trimester quadruple screen, where it is raised in Down syndrome; the four markers together found 81 per cent of cases at a 5 per cent false-positive rate 2
- A tumour marker for granulosa cell tumours of the ovary: in the first series, it was already raised 5 and 20 months before a recurrence showed itself 3
- Low in early pregnancy failure, alongside hCG and progesterone
Beyond the body’s own use
- Nothing is given as inhibin A and nothing blocks it in particular. The activin traps approved for anaemia and for pulmonary hypertension work on the other side of the same system
- Its screening job is being displaced by cell-free DNA testing, which reads fetal chromosomes directly, so the quadruple screen is now the second line where DNA testing is not available
Sources
- Welt et al., Female reproductive aging is marked by decreased secretion of dimeric inhibin, Journal of Clinical Endocrinology and Metabolism 1999
- Malone et al., First-trimester or second-trimester screening, or both, for Down’s syndrome, New England Journal of Medicine 2005
- Lappöhn et al., Inhibin as a marker for granulosa-cell tumors, New England Journal of Medicine 1989
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.